Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker PCSA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Ga… NCT05270460 · Gastroparesis PCS12852, Placebo | PCSA Processa Pharmaceuticals | Phase 2 | Completed | 25 | Sep 29, 2022 | Registry ↗ |
| Oct 22, 2026 | A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica NCT03698864 · Necrobiosis Lipoidica PCS499 | PCSA Processa Pharmaceuticals | Phase 2 | Completed | 12 | Feb 25, 2020 | Registry ↗ |
| Oct 6, 2026 | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer NCT06568692 · Breast Cancer, TNBC - Triple-Negative Breast Cancer PCS6422 and capecitabine, Capecitabine | PCSA Processa Pharmaceuticals | Phase 2 | Terminated | 20 | Jul 29, 2026 | Registry ↗ |
| Oct 10, 2024 | A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, R… NCT04861987 · Advanced Cancer, Refractory Cancer PCS6422 and capecitabine | PCSA Processa Pharmaceuticals | Phase 1 | Completed | 23 | Jun 12, 2024 | Registry ↗ |
| Dec 6, 2023 | RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer NCT03189914 · Metastatic Pancreatic Cancer RX-3117 | PCSA Processa Pharmaceuticals | Phase 1/2 | Completed | 46 | Oct 1, 2019 | Registry ↗ |
| Dec 6, 2023 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies NCT02030067 · Solid Tumor, Metastatic Bladder Cancer RX-3117 | PCSA Processa Pharmaceuticals | Phase 1/2 | Completed | 127 | Jul 2019 | Registry ↗ |
| Aug 3, 2023 | A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoid… NCT04800562 · Necrobiosis Lipoidica PCS499, placebo | PCSA Processa Pharmaceuticals | Phase 2 | Terminated | 4 | Feb 28, 2023 | Registry ↗ |
| Sep 3, 2020 | Open Label Extension Study of HT-100 in Patients With DMD NCT01978366 · Duchenne Muscular Dystrophy HT-100 | PCSA Processa Pharmaceuticals | Phase 2 | Terminated | 17 | Apr 30, 2016 | Registry ↗ |
| Sep 3, 2020 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscu… NCT01847573 · Duchenne Muscular Dystrophy HT-100 | PCSA Processa Pharmaceuticals | Phase 1/2 | Terminated | 17 | Mar 30, 2016 | Registry ↗ |
| Feb 12, 2019 | Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS4… NCT03836222 · Healthy PCS499, Trental | PCSA Processa Pharmaceuticals | Phase 1 | Completed | 18 | Jun 4, 2018 | Registry ↗ |
10 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances